evidence: This multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial evaluated the efficacy, immunogenicity, and safety of two doses (day 0 and day 28) of CoronaVac® in healthy children and adolescents aged from 6 months to 17 years. Participants were enrolled from Chile, South Africa, Malaysia, and the Philippines, with 37 sites. The enrollment ran from September 10, 2021, to March 25, 2022. [...] Palacios, R. et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials21, 853 (2020).